Modus Therapeutics Holding AB (publ)

Stockholm Stock Exchange MODTX.ST

Modus Therapeutics Holding AB (publ) EPS (Diluted) for the year ending December 31, 2023: USD -0.10

Modus Therapeutics Holding AB (publ) EPS (Diluted) is USD -0.10 for the year ending December 31, 2023, a 8.43% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Modus Therapeutics Holding AB (publ) EPS (Diluted) for the year ending December 31, 2022 was USD -0.11, a 40.79% change year over year.
  • Modus Therapeutics Holding AB (publ) EPS (Diluted) for the year ending December 31, 2021 was USD -0.18.
  • Modus Therapeutics Holding AB (publ) EPS (Diluted) for the year ending December 31, 2019 was USD -0.29, a 16.78% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
SV Wall Street
Stockholm Stock Exchange: MODTX.ST

Modus Therapeutics Holding AB (publ)

CEO Dr. John Öhd M.D., Ph.D.
IPO Date July 22, 2021
Location Sweden
Headquarters Olof Palmes gata 29 IV
Employees 2
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals Plastics Vaccines
Description

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.

StockViz Staff

February 4, 2025

Any question? Send us an email